OVARIAN CANCER and US: phase 11 - Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma - Full Text View - ClinicalTrials.gov (not yet recruiting)

Tuesday, June 28, 2011

phase 11 - Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma - Full Text View - ClinicalTrials.gov (not yet recruiting)

Biological: Chimeric monoclonal antibody (TRC105) to CD105

10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle

Other Names:

TRC105
NSC#754227

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.